The largest cluster included 43 dysregulated pathways related to up-regulation of signaling in AD, including NFKB (nuclear factor kappa-light-chain-enhancer) activation, MAPK (mitogen-activated protein kinases) activation, and FAK (focal adhesion kinase) signaling. This evidence concerns the gene NFKB1 and Alzheimer disease.